Search Results

Kiyatec, a leading biotechnology company specializing in 3D cell culture technology, is pleased to announce the promotion of Eric Perreault to the position of chief executive officer.

Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec’s 3D Spheroid Screening Platform, KIYA-Predict TM.

Kiyatec is pleased to announce that Mark Capone, former CEO of Myriad Genetics, has joined its team as a strategic advisor.

Kiyatec, the leader in clinically correlated functional precision oncology, and XenoSTART, the worldwide leader in patient derived xenograft model development, have formally announced their ongoing collaboration to help biopharma more rapidly assess efficacy with XenoSTART’s Patient Derived Xenograft (XPDX) models, using Kiyatec’s ex vivo 3D spheroid screening platform.

Kiyatec, a leading biotechnology company specializing in 3D cell culture technologies, is pleased to announce the appointment of Eric Perreault to the position of President.

Kiyatec, Inc., the leader in functional precision oncology, announced a new investment from the venture philanthropy arms of two leading brain tumor patient organizations.

Kiyatec, the leader in clinically correlated, published functional precision oncology technology, today announced that two abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting to be held in Orlando, Florida from April 14 – 19, 2023.

Kiyatec Inc. announced a closing of its Series C funding round totaling US$18 million from new and existing investors.

Kiyatec announced the company is sponsoring and exhibiting at the virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022.

KIYATEC today announced that six abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022